Smith+Nephew in the news

Smith+Nephew launched its CARTIHEAL AGILI-C Cartilage Repair Implant in Europe, showing superior knee pain relief and functional outcomes in a five-year trial compared to standard surgery.

Jami Bliss has been promoted to Chief Procurement Officer at Smith+Nephew, bringing her extensive experience in supply management and procurement transformation to the medical technology company.

Smith & Nephew is redeeming dollar notes maturing next year, following strong financial results and ahead of its November quarterly report, while also promoting its shoulder technologies.

Smith & Nephew launched its CartiHeal Agili-C cartilage repair implant in Europe, designed to restore bone and relieve pain with demonstrated clinical effectiveness.

Smith+Nephew launched its CARTIHEAL AGILI-C Cartilage Repair Implant in Europe, a device designed to repair cartilage and restore bone, following its successful introduction in the US.

Smith+Nephew has launched its CARTIHEAL AGILI-C Cartilage Repair Implant in Europe, an aragonite-based device designed to repair cartilage and restore bone in knees, following its successful US introduction.

Smith & Nephew has launched its Cartiheal Agili-C Cartilage Repair Implant in Europe, a move expanding its orthopedic solutions while the company demonstrates strong financial health with a 3.02% dividend yield and an undervalued stock price.

Smith & Nephew's 5.150% Notes due 2027 are being delisted from the New York Stock Exchange through a voluntary withdrawal.

Smith & Nephew PLC will pay a $0.31 per share dividend on November 6, 2026, supported by high profitability but facing mixed growth rates compared to competitors.

Smith+Nephew highlighted new and existing shoulder repair and reconstruction technologies at a medical congress, with its stock showing a slight increase.

Smith & Nephew is redeeming its $350,000,000 5.150% Notes due 2027 on October 5, 2026, at a price of 100.245% plus accrued interest.

Smith & Nephew reported its issued share capital and voting rights as of September 30, 2026, with 837,432,536 ordinary shares carrying voting rights.

Smith & Nephew plc announced the redemption price for its $350 million 5.150% Notes due 2027, to be redeemed on October 5, 2026.

Smith & Nephew reported 4.60% H1 2026 revenue growth to $3.10 billion and an 8.10% increase in trading profit, despite mixed underlying segment growth and a decline in free cash flow.

Smith+Nephew introduced the EVOS PELVIC Plating System, enhancing its trauma portfolio for pelvic and acetabular fractures with advanced features for surgical efficiency.

Smith & Nephew's stock reached a new low amid debt refinancing and a new product launch, with the company focusing on orthopaedics, sports medicine, and wound management.

AlphaValue/Baader Europe downgraded Smith & Nephew to an 'Add' rating based on various composite financial and investment metrics.

Smith & Nephew is proactively restructuring its debt through bond redemptions and new issuances to optimize its financial structure and support strategic investments.

Smith & Nephew plc has an upcoming dividend with a 2.9% trailing yield, which is well-covered by earnings and cash flow, and has shown modest growth in EPS and dividends.

Smith+Nephew introduced the EVOS PELVIC Plating System, an advanced solution for managing complex pelvic and acetabular fractures.